New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:25 EDTTSPT, PFE, NKE, WAG, HALO, RHT, RIMM, CEMIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Red Hat (RHT), up 5.4%... Nike (NKE), up 3%... ALSO HIGHER: Chembio Diagnostics (CEMI), up 20.7% after receiving FDA approval for its rapid HIV test... Halozyme (HALO), up 17.4% after entering a development collaboration with Pfizer (PFE)... Ameristar Casinos (ASCA), up 17% after agreeing to be acquired by Pinnacle Entertainment (PNK) for $26.50 per share... LOWER AFTER EARNINGS: Research in Motion (RIMM), down 16.3%... Walgreen (WAG), down 1.7%... ALSO LOWER: Transcept (TSPT), down 14.7% after Phase 2 trial of OCD drug misses primary endpoint.
News For RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
11:30 EDTWAGLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:00 EDTRHT, NKEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:14 EDTRHTRed Hat downgraded at Wells Fargo
As noted earlier, Wells Fargo downgraded Red Hat to Market Perform from Outperform. The firm downgraded the stock based on valuation. Target $64-$68.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
06:38 EDTNKENike downgraded to Market Perform from Outperform at Telsey Advisory
Subscribe for More Information
05:54 EDTRHTRed Hat downgraded to Market Perform from Outperform at Wells Fargo
December 5, 2014
10:22 EDTPFEBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTPFEBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
December 4, 2014
13:15 EDTNKENike, Adidas open stores for women in China, WantChinaTimes says
Subscribe for More Information
10:10 EDTWAGWalgreen names Linda Filler as Chief Merchandising Officer
Subscribe for More Information
09:26 EDTWAGUnion group launches fight against Walgreen deal for Boots, WSJ reports
CtW Investment Group, an arm of labor group Change to Win that represents union pension funds that own about 0.3% of Walgreen argued in a letter sent to nearly all other shareholders that the company's $14.7B plan to buy the remaining 55% stake in Alliance Boots is overpriced and unnecessary, reported The Wall Street Journal. Reference Link
08:45 EDTPFEAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
08:14 EDTRHTRed Hat, Huawei announce OpenStack collaboration pact
Subscribe for More Information
December 3, 2014
17:12 EDTPFEPfizer reports positive results from PROFILE 1014 study
Subscribe for More Information
16:42 EDTPFEDiplomat chosen as limited-distribution pharmacy partner by Pfizer
Subscribe for More Information
08:08 EDTWAGWalgreen reports Q1 sales $19.59B, consensus $19.34B
Subscribe for More Information
08:01 EDTWAGWalgreen reports November SSS up 4.5%
Subscribe for More Information
07:16 EDTPFEFood & Drug Law Institute to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use